Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
DOI
PMC
 |
Open Access Gold |
|
as soon as is submitted to ZB.
The role of miRNA for the treatment of MGMT unmethylated glioblastoma multiforme.
Cancers 12:1099 (2020)
Glioblastoma multiforme (GBM) is the most common high-grade intracranial tumor in adults. It is characterized by uncontrolled proliferation, diffuse infiltration due to high invasive and migratory capacities, as well as intense resistance to chemo- and radiotherapy. With a five-year survival of less than 3% and an average survival rate of 12 months after diagnosis, GBM has become a focus of current research to urgently develop new therapeutic approaches in order to prolong survival of GBM patients. The methylation status of the promoter region of the O-6-methylguanine-DNA methyltransferase (MGMT) is nowadays routinely analyzed since a methylated promoter region is beneficial for an effective response to temozolomide-based chemotherapy. Furthermore, several miRNAs were identified regulating MGMT expression, apart from promoter methylation, by degrading MGMT mRNA before protein translation. These miRNAs could be a promising innovative treatment approach to enhance Temozolomide (TMZ) sensitivity in MGMT unmethylated patients and to increase progression-free survival as well as long-term survival. In this review, the relevant miRNAs are systematically reviewed.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Glioblastoma ; Mirna ; Mgmt ; Survival ; Radiotherapy ; Chemotherapy ; Temozolomide ; Translational Medicine; Temozolomide Plus O-6-benzylguanine; Newly-diagnosed Glioblastoma; Dna-repair Protein; Human Glioma-cells; Cancer Stem-cells; Phase-ii; Malignant Progression; Adjuvant Temozolomide; Current Strategies; Genetic Pathways
ISSN (print) / ISBN
2072-6694
Journal
Cancers
Quellenangaben
Volume: 12,
Issue: 5,
Article Number: 1099
Publisher
MDPI
Publishing Place
St Alban-anlage 66, Ch-4052 Basel, Switzerland
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Radiation Medicine (IRM)